: 19933938  [PubMed - indexed for MEDLINE]1020. N Engl J Med. 2009 Dec 3;361(23):2241-51. doi: 10.1056/NEJMoa0909938. Epub 2009Nov 17.Advanced heart failure treated with continuous-flow left ventricular assistdevice.Slaughter MS(1), Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, Sun B,Tatooles AJ, Delgado RM 3rd, Long JW, Wozniak TC, Ghumman W, Farrar DJ, FrazierOH; HeartMate II Investigators.Collaborators: Sobieski M, Gallagher C, Pappas P, Silver M, Lodge A, Blue L, ShahA, Yuh D, Ullrich S, Dordunoo D, Rivard D, Kar B, Radovancevic B, Gregoric I,Civitello A, Massin E, Gemmato C, Jafar M, Bogaev R, Smart F, Sirak J, SudhakerS, Yanssens T, Reid B, Horton S, Renland D, Revenaugh J, Eidson M, Turrentine M, Becka S, Dean D, Murali S, Magovern G, Bailey S, Sokos G, Kernickey L, Moazami N,Ewald G, Shelton K, Anderson D, Wang I, Garrett E, Edwards T, Carter R, Porter C,Shekar P, Couper G, Givertz M, Kelly S, Raines E, Miller K, McClement-Green L,Haeusslein E, Avery GJ, Brandenhoff P, Carnam J, Oka T, Courville R, Smedira N,Starling R, Navia J, Gonzalez G, Mihaljevic T, Teague L, Naka Y, Idrissi K,Stewart A, Vega D, Smith A, Laskar R, Thompson J, Entwistle J, Eisen H, HankinsS, Metzger T, Brewer R, Czerska B, Williams C, Braxton B, Pae W, Boehmer J,Stephensen T, Lazar M, Myers A, Acker M, Jessup M, Morris R, Desai S, O'Hara M,Long J, Horstmanshof D, Chaffin J, Elkins C, Kanaly P, Leiker E, Gray L, Dowling R, Pagni S, Bhat G, Adkisson P, Prabu S, Sharma R, Aggarwal S, MacGillivray T,Agnihotri A, Madsen J, Vlahakes G, Rosengard B, Semigran M, Ennis S, Camuso J,Daly R, Park S, Durham L, Edwards B, Anderson C, Penev I, Arabia F, DeValeria P, Guyah E, Lanza L, Scott R, Steidley E, McAleer K, Dewey T, Magee M, Mack M,Anderson A, Worley T, Goldstein D, Maybaum S, D'Alessandro D, McAllister N,Brooks K, Denofrio D, Pham D, Rastegar H, Ehsan A, Cote H, Camacho M, Zucker M,McBride L, Shah S, Carr C, Cecere R, Giannetti N, Barber C, Icenogle T, EverettJ, Sandler D, Pulhman M, Rich J, Herre J, Pine L, Fleischer K, McGrath M, KlodellC, Aranda J, Staples N, Dembitsky W, Jaski B, Adamson R, Baradarian S, Chillcott S, Tector A, Pisani B, Crouch J, Downey F, Kress D, McDonald M, O'Hair D, Savitt M, Miller M, Sheffield C, Caldeira C, DiChiara L, Rao V, MacIver J, Kirklin J,Bourge R, McGiffin D, Pamboukian S, Rayburn B, Tallaj J, Baldwin D, Cleveland J, Lindenfeld J, Brieke A, Reece B, Shakar S, Wolfel E, Cannon A, Griffith B, FellerE, Brown J, Romar L, Pagani F, Aaronson K, Haft J, Koelling T, Dyke B, Devaney E,Wright S, McGowan L, Boyle A, John R, Joyce L, Colvin-Adams M, Missov E, ToninatoC, Kormos R, McNamara D, Lockard K, Massey T, Chen L, Hallinan W, Chiodo V,Hobart P, Verrier E, Fishbein D, Salerno C, Aldea G, Andrus S, Mokadam N, EdwardsN, Johnson M, Kao W, Kohmoto T, Yakey J, Li A, Boyce S, Miller L, Sweet L, Petro K, Shah M, Miller L, Pagani F, Frazier O, Russell S, Naka Y, Slaughter M, Farrar D, Yancy C, Hunt S, Holman W, Richenbacher W, Heitjan D, Moore S, Jeevanandam V, Thomas C, Gordon S, Damme L, Heatley J, Reichenbach S.Comment in    N Engl J Med. 2009 Dec 3;361(23):2282-5.    N Engl J Med. 2010 Mar 25;362(12):1149; author reply 1149.BACKGROUND: Patients with advanced heart failure have improved survival rates andquality of life when treated with implanted pulsatile-flow left ventricularassist devices as compared with medical therapy. New continuous-flow devices are smaller and may be more durable than the pulsatile-flow devices.METHODS: In this randomized trial, we enrolled patients with advanced heartfailure who were ineligible for transplantation, in a 2:1 ratio, to undergoimplantation of a continuous-flow device (134 patients) or the currently approvedpulsatile-flow device (66 patients). The primary composite end point was, at 2years, survival free from disabling stroke and reoperation to repair or replacethe device. Secondary end points included survival, frequency of adverse events, the quality of life, and functional capacity.RESULTS: Preoperative characteristics were similar in the two treatment groups,with a median age of 64 years (range, 26 to 81), a mean left ventricular ejectionfraction of 17%, and nearly 80% of patients receiving intravenous inotropicagents. The primary composite end point was achieved in more patients withcontinuous-flow devices than with pulsatile-flow devices (62 of 134 [46%] vs. 7of 66 [11%]; P<0.001; hazard ratio, 0.38; 95% confidence interval, 0.27 to 0.54; P<0.001), and patients with continuous-flow devices had superior actuarialsurvival rates at 2 years (58% vs. 24%, P=0.008). Adverse events and devicereplacements were less frequent in patients with the continuous-flow device. The quality of life and functional capacity improved significantly in both groups.CONCLUSIONS: Treatment with a continuous-flow left ventricular assist device inpatients with advanced heart failure significantly improved the probability ofsurvival free from stroke and device failure at 2 years as compared with apulsatile device. Both devices significantly improved the quality of life andfunctional capacity. (ClinicalTrials.gov number, NCT00121485.)2009 Massachusetts Medical Society